extreme sport betting
China's Xi to lead Macau handover anniversary celebrations
CELH Investors Have Opportunity to Lead Celsius Holdings, Inc. Securities Fraud Lawsuit
ZURICH (AP) — Saudi Arabia scored a major win in its campaign to attract major sports events to the kingdom when it was formally appointed as the 2034 World Cup host on Wednesday. Still, many questions remain about the tournament as well as the 2030 World Cup, which will be co-hosted by Spain, Portugal and Morocco, with three games in South America. Here are some of the key issues that need to be answered over the next decade: Saudi Arabia proposes 15 stadiums — eight still on paper — in five cities: Eight in the capital Riyadh, four in the Red Sea port city Jeddah, and one each in Abha, Al Khobar and Neom, the planned futuristic mega-project. Each would have at least 40,000 seats for World Cup games. The opening game and final are set for a 92,000-seat venue planned in Riyadh. Some designs are vivid . In Neom, the stadium is planned 350 meters (yards) above street level and one near Riyadh is designed to be atop a 200-meter cliff with a retractable wall of LED screens. Saudi Arabia aims to host all 104 games, though there has been speculation that some games could be played in neighboring or nearby countries. Surely not in the traditional World Cup period of June-July, when temperatures in Saudi Arabia routinely exceed 40 Celsius (104 degrees). FIFA moved the Qatar-hosted World Cup to November-December 2022, though those dates were not loved by most European clubs and leagues whose seasons were interrupted. Also, that slot is complicated in 2034 by the holy month of Ramadan through mid-December and Riyadh hosting the multi-sport Asian Games. January 2034 could be a possibility even though that would be just before the Winter Olympics in Salt Lake City. The International Olympic Committee has signaled it won’t be opposed to back-to-back major events. In an interview with The Associated Press on Wednesday, Saudi World Cup bid official Hammad Albalawi said the precise dates of the tournament are up the world soccer body. “That’s a decision by FIFA. We stand ready to be part of this conversation. But ultimately it’s a FIFA decision together with the confederations,” Albalawi said. Giving more rights and freedoms to women in a traditionally conservative society is fundamental to Saudi messaging around the modernization program known as Vision 2030. The kingdom decided in 2017 to let women attend sports events, initially in major cities and in family zones separate from men-only sections. By 2034, at the promised pace of social reforms, female fans should not be restricted. Saudi Arabia launched a women’s professional soccer league in 2022 with players joining from clubs in Europe. They face no restrictions playing in shorts and with hair uncovered. The Saudi prohibition of alcohol is clear and understood before FIFA signs any sponsor deals for 2034. But will there be any exceptions? The alcohol issue was problematic for the World Cup in Qatar because the expectation was created that beer sales would be allowed at stadiums even before Qatar won its bid in 2010. One year later, FIFA extended a long-time deal to have Budweiser as the official World Cup beer through 2022. Qatar then backtracked on that promise three days before the first game, causing confusion and the sense of a promise broken. In Qatar, alcohol was served only at luxury suites at the stadiums. Visitors could also have a drink in some hotel bars. But Saudi Arabia has even stricter rules on alcohol — and there is no indication that will change. Albalawi noted that Saudi Arabia has successfully hosted dozens of sports events where alcohol wasn't served. “We’re creating a safe and secure family environment for fans to bring their families into our stadiums,” he said. Saudi promises to reform and enforce labor laws, and fully respect migrant workers, have been accepted by FIFA but face broad skepticism from rights groups and trade unions. A formal complaint is being investigated by the U.N.-backed International Labor Organization. Protecting the migrant workers needed to build stadiums and other tournament projects — a decade after it was a defining issue for Qatar — looms as a signature challenge for Saudi Arabia. Saudi-Israeli relations had been improving when FIFA all but gave the 2034 World Cup to the kingdom on Oct. 4 last year. Three days later Hamas attacked Israel and diplomacy got more complicated. Any soccer federation bidding to host a FIFA tournament accepts a basic principle that whichever team qualifies is welcome. That did not stop Indonesia putting up barriers last year to Israel coming for the men’s Under-20 World Cup. Indonesia does not have formal diplomatic relations with Israel which had qualified through a European tournament nine months before the issue flared. FIFA moved the entire tournament to Argentina and the Israeli team reached the semifinals. Israel played at the 1970 World Cup but has never advanced through qualifying in Europe, where it has been a member of UEFA for 30 years. Europe should have 16 places in the 48-team World Cup in Saudi Arabia. Most of the attention at the FIFA Congress on Wednesday was on the Saudi decision, but the soccer body and its members also formally approved the hosts of the 2030 World Cup — the most spread out and longest ever. One game each in Argentina, Paraguay and Uruguay, the original host in 1930, will be played from June 8-9. The tournament resumes four days later for the other 101 games shared between Spain, Portugal and Morocco. Six countries, three continents, multiple languages and currencies. Fans traveling on planes, trains, automobiles and boats across about 14 kilometers (10 miles) of water between Spain and Morocco. The final is due on July 21, 2030 and a decision on where it will be played could cause some tension between the host countries. Morocco wants it in the world’s biggest soccer venue — the planned 115,000-seat King Hassan II Stadium in Casablanca. Spain, meanwhile, has proposed to host the final in either of the remodeled home stadiums of club giants Real Madrid or Barcelona. Associated Press writer Baraa Anwer in Riyadh, Saudi Arabia, contributed to this report.‘Friends’-themed game show premiering on Max later this monthKroger Reiterates Its Commitment to Lower Prices and Initiates New $7.5B Share Buyback Program
NEW YORK , Nov. 22, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zeta Global Holdings Corp. (NYSE: ZETA) resulting from allegations that Zeta Global may have issued materially misleading business information to the investing public. So What: If you purchased Zeta Global securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=31333 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. What is this about: On November 13, 2024 , Culper Research published a report entitled "Zeta Global Holdings Corp ZETA: Shams, Scams, and Spam." (the "Report"). The Report raised concerns about the company's reported financials. In addition, Culper Research announced that it believed that "Zeta has quietly spun up its own network of consent farms i.e., sham websites that hoodwink millions of consumers each month into handing their data over to Zeta under false pretenses, baited by job applications, stimulus money, or other rewards that simply do not exist." On this news, Zeta Global's stock price fell 37.1% on November 13, 2024 . Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-zeta-global-holdings-corp-investors-to-inquire-about-securities-class-action-investigation--zeta-302314487.html SOURCE THE ROSEN LAW FIRM, P. A.Romania's pro-Western parties agree to form majority government after political turmoil
Article content Toyota has announced upgrades to its all-electric bZ4X for 2025, including a new mid-range trim level. The bZ4X, also the basis of the Subaru Solterra , is currently sold only in British Columbia and Quebec. While the 2024 version came as the LE in front-wheel drive (FWD) and the XLE in all-wheel drive (AWD), the new LE AWD trim slides in between them. Pricing for the 2025 bZ4X starts at $46,515 for the LE FWD; $47,016 for the new LE AWD; $51,845 for the XLE AWD; and the Technology Package takes it to $59,830. The vehicle is eligible for provincial “green” vehicle rebates in B.C. and Quebec, as well as the federal rebate . The 2025 XLE AWD model now receives a steering wheel touch-sensor system, front cross-traffic alert, and lane change assist; and its Technology Package now includes traffic jam assist, using adaptive cruise control at stop-and-go speeds. While Subaru hasn’t yet announced any changes to the Solterra for 2025, the 2024 version comes only in AWD, and in a basic trim but with available Luxury Package or Technology Package options. Seating up to five passengers, the bZ4X – a number-and-letter salad that we at Driving remember by thinking of “busy forest” – has a single electric motor in the FWD model, making 201 horsepower and 196 lb-ft of torque, and with a range of up to 406 km. The AWD trims add a second rear electric motor, with a combined rating of 214 horsepower and 248 lb-ft of torque, with a range of up to 367 km. Standard features on the LE models include a 12.3-inch touchscreen with Toyota Multimedia operating system, heated front seats with radiant foot and leg warmer, dual-zone climate control, and heated steering wheel. Driver-assist technologies include emergency front braking, adaptive cruise control, lane-keep assist, safe exit assist, and blind-spot monitoring with rear cross-traffic alert. The XLE AWD adds faux-leather upholstery trim, auto-dimming mirror, panoramic sunroof, garage door opener, rear-seat charging ports, cargo cover, and rear cross-traffic braking. Its available Technology Package further adds 20-inch wheels, connectivity services, premium audio, full leather-look upholstery, heated and ventilated front seats, hands-free liftgate, roof rails, panoramic view monitor, advanced parking system, and digital key, plus the new traffic jam assist. Sign up for our newsletter Blind-Spot Monitor and follow our social channels on Instagram , Facebook and X to stay up to date on the latest automotive news, reviews, car culture, and vehicle shopping advice.Shiffrin crashes out of Killington giant slalom won by Hector
Optex Systems Holdings, Inc. Announces Financial Highlights for the Year Ended September 29, 2024Fort Worth-based unmanned airship technology firm receives key FAA certification
Trump nominates Kash Patel to serve as FBI director
( MENAFN - ACN NewsWire) Hua medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC SHANGHAI, Nov 30, 2024 - (ACN Newswire) - Hua Medicine (the“Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and investment conference (CBIIC). The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation. The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients. Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients. About Hua Medicine Hua Medicine (The“Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. For more information Hua Medicine Website: Investors E-mail: ... Media E-mail: ... MENAFN30112024002725003249ID1108941843 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Meghan McCain says she voted for late father in 2024 presidential election
MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. SGHT ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis ("BIA") of the TearCare ® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States. A BIA estimates the fiscal impact of adopting a new technology or treatment within a specific provider environment or patient population – in this case, identifying the health savings associated with increased adoption of TearCare as compared to prescription dry eye medications for patients with DED.* The analysis, projected over a two-year period, focused on moderate to severe MGD- associated DED in U.S. patients over 18 years of age. It compared the financial impact of TearCare to commonly prescribed dry eye medications, including Restasis 0.05% branded and generic, and Xiidra 5%. Key findings indicated that a 20% increase in market share of TearCare compared to prescription dry eye medications would yield an estimated annual savings of $36.87 per member per year ("PMPY") in a hypothetical health plan with one million covered lives. The study showed a direct relationship between increased utilization of TearCare in place of prescription medications and total costs savings from a US payer perspective. "In addition to the strong clinical efficacy of TearCare shown in the SAHARA and OLYMPIA randomized controlled trials, this budget impact analysis reported that increased adoption of TearCare treatments for patients with MGD-associated DED was estimated to result in meaningful cost savings. We believe the combination of the strong clinical data from the SAHARA RCT and the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "Pioneering market access to interventional dry eye treatments with TearCare on behalf of patients and the eye care providers who care for them is a core component of our strategy and this milestone represents progress towards delivering this innovative technology to a portion of the 17.9 million patients diagnosed with dry eye disease in the U.S." Authors and affiliations : Phoenix Riley, PharmD, MSc (AESARA, Inc.); Cristina Masseria, PhD (AESARA, Inc.); Chad Patel, PharmD (AESARA, Inc.); Roberta Longo, PhD (AESARA, Inc.); Lorie Mody, PharmD (AESARA, Inc.), and Thomas Chester, OD, FAAO (Cleveland Eye Clinic). *The BIA was developed in accordance with established ISPOR guidelines, but it was based upon various assumptions, including with respect to cost of treatments, respective usage and market uptake of prescription drops and TearCare, efficacy (including duration of effect), safety and similar factors. These assumptions may not be consistent with actual clinical and market conditions, and changes in one or more of these assumptions could cause individual health plan results to differ. Paper Reference: Chester, T., Longo, R., Masseria, C., Riley, P., Patel, C., & Mody, L. (2024). Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Expert Review of Ophthalmology , DOI: 10.1080/17469899.2024.2444930. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI ® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's SION ® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to Meibomian Gland Disease ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by eyecare providers to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com . Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2024 Sight Sciences. All rights reserved. Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding estimated costs savings associated with use of the TearCare System; and the belief that the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Media contact pr@SightSciences.com Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.CELH Investors Have Opportunity to Lead Celsius Holdings, Inc. Securities Fraud Lawsuit
NoneKochi: A comprehensive, radical shift in Kerala's higher education sector is essential, Minister R Bindu said. The minister emphasized that higher educational institutions in the state are playing a key role in creating a knowledge-based society with a focus on bridging the gap between education and employment and promoting students' entrepreneurial interests. Bindu, the minister of higher education in the state, was addressing a meeting of committees set up to conduct the ' Shaping Kerala's Future - International Conclave on Next-Gen Higher Education ,' organized by the Kerala State Council for Higher Education at Cochin University of Science and Technology (Cusat) here, a press release issued by the university on Saturday said. The international conclave will take place on January 14 and 15 next year at Cusat. Minister R Bindu noted that the conclave, which was announced in response to the rapid pace of global changes, is part of the state government's vision, the release stated. Law Minister P Rajeev, who was the chief guest at the meeting, said that Kerala is set to enter an era of 'brain gain' and reverse migration. He emphasized that higher educational institutions are key to solving industry challenges. He also said an ecosystem where researchers, academia, and industry can collaborate was essential. Leadership Building Your Winning Startup Team: Key Strategies for Success By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Leadership Boosting Startup Revenue with 6 AI-Powered Sales Automation Techniques By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Leadership From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Web Development Advanced Java Mastery: Object-Oriented Programming Techniques By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Startup Fundraising: Essential Tactics for Securing Capital By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Java 21 Essentials for Beginners: Build Strong Programming Foundations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Leadership Validating Your Startup Idea: Steps to Ensure Market Fit By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Artificial Intelligence(AI) AI for Everyone: Understanding and Applying the Basics on Artificial Intelligence By - Ritesh Vajariya, Generative AI Expert View Program Web Development Intermediate C++ Skills: Master Pointers, Structures and File Stream By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Tabnine AI Masterclass: Optimize Your Coding Efficiency By - Metla Sudha Sekhar, IT Specialist and Developer View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Web Development Master RESTful APIs with Python and Django REST Framework: Web API Development By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Data Science MySQL for Beginners: Learn Data Science and Analytics Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Tally Prime & GST Accounting: Complete Guide By - CA Raj K Agrawal, Chartered Accountant View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Marketing Marketing & Sales Strategies for Startups: From Concept to Conversion By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Minister Rajeev added that conferences like this will significantly influence policy-making, driving change and enabling reverse migration through advancements in both industrial and educational sectors. The conclave aims to discuss innovative approaches and share excellence in research and academics, offering a platform to address the challenges and opportunities of the 21st century, the release said. Plenary and parallel sessions will cover topics such as Kerala's global perspective on education, research excellence, economic sustainability, artificial intelligence, the role of research in policy-making, changes in the workplace and teaching sectors, and the impact of student unions on higher education, it added. The meeting also proposed conducting various pre-conclave events at Kochi's leading educational institutions, the release said. (You can now subscribe to our Economic Times WhatsApp channel )
There is always that one dish on the Thanksgiving table – overlooked while the mashed potatoes and gravy steal the spotlight. Surprisingly, this much-maligned side dish has been a part of American tradition for centuries and holds endless possibilities beyond its original purpose, perfectly suited to be reinvented in unexpected ways. Despite its deep roots in Thanksgiving history, this dish remains one of the most polarizing items on the table today. What is this least popular Thanksgiving dish? Cranberry sauce. Cranberry sauce has been part of American cuisine for centuries. Native Americans used cranberries in cooking and medicine, and early European settlers followed suit, incorporating the berries into sauces and preserves. By the 19th century, cranberry sauce became a Thanksgiving tradition, although recipes varied by region. The introduction of canned cranberry sauce in the 20th century made it even more popular, cementing its spot as an expected accompaniment for on tables across the country. Those who do enjoy cranberry sauce probably have a strong opinion about what form is acceptable. Some people prefer canned cranberry sauce for its nostalgic jiggle, while others insist that fresh, homemade cranberry sauce is the only way to go. Homemade whole berry sauce is the top choice for many, with its texture and flavor offering something truly special. A 2021 by the grocery delivery service Instacart found that cranberry sauce is the least favorite Thanksgiving dish, with 29% of American adults saying they hate it and nearly 50% calling it disgusting. This makes cranberry sauce the most polarizing and the most disliked dish on the Thanksgiving table. Even though it ranks as the least favorite dish, omitting cranberry sauce from the holiday meal is still considered a bit of a . Regardless of what kind of cranberry sauce graces the table, its lack of popularity guarantees leftovers. But do not let those leftovers go to waste; there are plenty of creative and delicious ways to use cranberry sauce beyond the Thanksgiving table. Leftover cranberry sauce? There is no need to despair. Here are some fun, delicious and inventive ways to give those leftovers a new purpose. Cranberry sauce is the perfect addition to a grilled cheese sandwich. Layer sharp cheddar or brie cheese, turkey leftovers and a spoonful of cranberry sauce between two slices of sourdough bread. The tart cranberry cuts through the richness of the cheese for a perfectly balanced bite. To feed a crowd, consider making a casserole dish of with leftover sauce and turkey meat. To make a simple salad dressing, grab a mason jar and add a tablespoon of leftover cranberry sauce. Pour in a splash of white balsamic vinegar and an equal portion of olive oil. Add pinches of fresh herbs, salt and pepper. Secure the lid, shake well and drizzle the zesty cranberry vinaigrette over an autumn salad with lettuce, gorgonzola cheese, pecans and dried cranberries. For an easy homemade barbecue sauce, mix leftover cranberry sauce with ketchup or chili sauce, a dash of hot sauce or Worcestershire sauce, and a bit of brown sugar. The result is a tangy barbecue sauce that pairs beautifully with , roasted chicken or pork chops. Guests will never guess that the base of your homemade barbecue sauce was the leftover cranberry sauce from Thanksgiving. For a quick breakfast or snack, layer cranberry sauce with vanilla Greek yogurt and granola for a simple yet elegant autumn parfait. The sweetness of the granola and the tanginess of the cranberry sauce make for a great flavor balance. For bonus points, add a drizzle of maple syrup and pecans. Yes, cranberry sauce can be used in cocktails. To make a festive drink, shake a generous spoonful of cranberry sauce with vodka, a splash of orange juice and a squeeze of simple syrup. Add ice and a fresh rosemary sprig, and the result is a tart, refreshing cocktail perfect for the holiday season. Related Articles For centuries, cranberry sauce has been a staple on the American Thanksgiving table. While it continues to be viewed as a traditional holiday dish by most Americans, an emerging trend shows chefs, food bloggers and home cooks finding new ways to incorporate cranberry sauce into various recipes throughout the year. Cranberry sauce may never steal the spotlight during Thanksgiving dinner, where traditional dishes like mashed potatoes, buttery rolls and pies often take center stage. However, its creative uses can elevate it as a standout ingredient in the days that follow. As Thanksgiving cleanup commences and a bowl of leftover sauce remains, there is no need to worry. This underdog simply requires a bit of creativity to shine.Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi BioscienceWASHINGTON — Only about 2 in 10 Americans approve of President Joe Biden's decision to pardon his son Hunter after earlier promising he would do no such thing, according to a poll from The Associated Press-NORC Center for Public Affairs Research. That displeasure tracks with the bipartisan uproar in Washington that ignited over the president's about-face. The survey found that a relatively small share of Americans "strongly" or "somewhat" approve of the pardon, which came after the younger Biden was convicted on gun and tax charges. About half said they "strongly" or "somewhat" disapprove, and about 2 in 10 neither approve nor disapprove. The Democratic president said repeatedly that he would not use his pardon power for the benefit of his family, and the White House continued to insist, even after Republican Donald Trump's election win in November, that Biden's position had not changed — until it suddenly did. Hunter Biden leaves federal court Sept. 5 in Los Angeles after pleading guilty to federal tax charges. Eric Thayer, Associated Press "I know it's not right to believe politicians as far as what they say compared to what they do, but he did explicitly say, 'I will not pardon my son,'" said Peter Prestia, a 59-year-old Republican from Woodland Park, New Jersey, just west of New York City, who said he strongly disagreed with the move. "So, it's just the fact that he went back on his word." In issuing a pardon Dec. 1, Biden argued that the Justice Department had presided over a "miscarriage of justice" in prosecuting his son. The president used some of the same kind of language that Trump does to describe the criminal cases against him and his other legal predicaments. White House press secretary Karine Jean-Pierre said it was a decision that Biden struggled with but came to shortly before he made the announcement, "because of how politically infected these cases were" as well as "what his political opponents were trying to do." The poll found that about 4 in 10 Democrats approve of the pardon, while about 3 in 10 disapprove and about one-quarter did not have an opinion or did not know enough to say. The vast majority of Republicans and about half of independents had a negative opinion. President Joe Biden and son Hunter Biden walk Nov. 29 in downtown Nantucket Mass. Jose Luis Magana, Associated Press For some, it was easy to see family taking priority over politics. "Do you have kids?" asked Robert Jenkins, a 63-year-old Democrat who runs a lumber yard and gas station in Gallipolis, Ohio. "You're gonna leave office and not pardon your kid? I mean, it's a no-brainer to me." But Prestia, who is semiretired from working for a digital marketing conglomerate, said Biden would have been better off not making promises. Listen now and subscribe: Apple Podcasts | Spotify | RSS Feed | SoundStack | All Of Our Podcasts "He does have that right to pardon anybody he wants. But he just should have kept his mouth shut, and he did it because it was before the election, so it's just a bold-faced lie," Prestia said. Despite the unpopularity of his decision, the president's approval rating has not shifted meaningfully since before his party lost the White House to Trump. About 4 in 10 Americans "somewhat" or "strongly" approve of the way Biden is handling his job as president, which is about where his approval rating stood in AP-NORC polls since January 2022. Still, the pardon keeps creating political shock waves, with Republicans, and even some top Democrats, decrying it. Older adults are more likely than younger ones to approve of Biden's pardoning his son, according to the poll, though their support is not especially strong. About one-third of those ages 60 and older approve, compared with about 2 in 10 adults under 60. The age divide is driven partially by the fact that younger adults are more likely than older ones to say they neither approve nor disapprove of the pardon or that they do not know enough to say. About 6 in 10 white adults disapprove of the pardon, compared with slightly less than half of Hispanic adults and about 3 in 10 Black adults. Relatively large shares of Black and Hispanic Americans — about 3 in 10 — were neutral, the poll found. "Don't say you're gonna do something and then fall back," said Trinell Champ, 43, a Democrat from Nederland, Texas, who works in the home health industry and said she disapproved of the pardon. "At the end of the day, all you have is your word." Champ, who is Black, voted for Democratic Vice President Kamala Harris over Trump. "I just had my hopes up for her, but I wasn't 100% positive," she said. Champ also said she does not approve of Biden's handling of the presidency and thinks the country is on the wrong track. "While he was in office, I felt like I really didn't see a lot of changes," she said. "I just felt like everything just kind of stayed the same," Champ said. Overall, though, the pardon did not appear to be a driving factor in many Americans' assessment of Biden's job performance. The share of Black Americans who approve of the way he is handling his job as president did fall slightly since October, but it is hard to assess what role the pardon may have played. Sen. Joe Biden (D-Del.) carries both of his sons, Joseph R. III, left, and Robert H., during an appearance at the Democratic state convention last summer, 1972. At center is his wife Neilia Biden, who was killed in an auto crash, Dec. 20, 1972. With them are Governor-elect Sherman W. Tribbitt and his wife, Jeanne. (AP Photo) AP FILE Joseph Biden, the newly-elected Democratic Senator from Delaware, is shown in Washington, Dec. 12, 1972. (AP Photo/Henry Griffin) AP FILE 1972 - Is first elected to the Senate at age 29, defeating Republican Senator J. Caleb Boggs. Wins re-election in 1978, 1984, 1990, 1996 and 2002. The newly-elected Democratic senator from Delaware, Joe Biden, is shown, Dec. 13, 1972. AP FILE Sen. Joe Biden (D-Del.) kisses the cheek of an unidentified friend who offered consoling words after a memorial service in Wilmington, Del., Dec. 22, 1972, for Biden's wife Neilia, their 13-month-old daughter Naomi Christina, who perished in a car-truck crash. Biden's two sons were hospitalized with serious injuries. (AP Photo/Bill Ingraham) AP FILE December 18, 1972 - While Christmas shopping, Biden's first wife, Neilia Hunter Biden, and daughter, Naomi Biden, are killed in a car accident. His sons are badly injured, but survive. January 5, 1973 - Is sworn in as US senator of Delaware at son Beau Biden's bedside in the hospital. In this Jan. 5, 1973 file photo, four-year-old Beau Biden, foreground, plays near his father, Joe Biden, center, being sworn in as the U.S. senator from Delaware, by Senate Secretary Frank Valeo, left, in ceremonies in a Wilmington hospital. Beau was injured in an accident that killed his mother and sister in December 1972. Biden's father, Robert Hunter, holds the Bible. (AP Photo/File) AP FILE 1987-1995 - Chairman of the Senate Committee on the Judiciary. Sen. Joe Biden (D-Del.), chairman of the Senate Judiciary Committee, rubs his temples while speaking during confirmation hearings for Supreme Court nominee Robert H. Bork, Sept. 17, 1987, on Capitol Hill. (AP Photo/John Duricka) AP FILE June 9, 1987 - Enters the 1988 presidential race, but drops out three months later following reports of plagiarism and false claims about his academic record. Sen. Joe Biden (D-Del.) waves from his train as he leaves Wilmington, Del., after announcing his candidacy for president, June 9, 1987. At right, son Beau carries daughter; to Biden's right is his wife Jill and son Hunter. (AP Photo/George Widman) AP FILE February 1988 - Undergoes surgery to repair an aneurysm in an artery that supplies blood to the brain. Sen. Joseph Biden (D-Del.), wearing a University of Delaware baseball cap, leaves Walter Reed Army Hospital accompanied by his son Hunter Biden, Thursday, March 24, 1988, Washington, D.C. Biden had been in the hospital for 11 days so that surgeons could implant a small umbrella-like filter in a vein to prevent blood clots from reaching his lungs. (AP Photo/Adele Starr) AP FILE In this Oct. 12, 1991 file photo Senate Judiciary Committee Chairman Joe Biden, D-Del., points angrily at Clarence Thomas during comments at the end of hearings on Thomas' nomination to the Supreme Court on Capitol Hill. Sen. Edward Kennedy, D-Mass. looks on at right. (AP Photo/Greg Gibson, File) AP FILE January 20, 1990 - Introduces a bill that becomes the Violence Against Women Act (VAWA). The act addresses sexual assault and domestic violence. It is signed into law by President Bill Clinton in 1994. Sen. Joe Biden (D-Del.), left, stands behind a flag as Sen. Barbara Boxer (D-Calif.), second from right, along with other congresswomen meet reporters on Capitol Hill, Feb. 24, 1993, to discuss the Violence Against Women Act. From left are: Sen. Biden; Rep. Louise Slaughter (D-N.Y.); Rep. Pat Schroeder (D-Colo); Sen. Boxer; and Rep. Constance Morella of Maryland. (AP Photo/Barry Thumma) AP FILE In this April 9, 1993, file photo Sen. Joe Biden, D-Del. stands in front of a Danish armored personnel carrier at the UN-controlled Sarajevo Airport, making a statement about his trip to the besieged Bosnian capital. (AP Photo/Michael Stravato, File) AP FILE Sen. Joseph Biden, D-Del., ranking Democrat on the Senate Foreign Relations Committee, meets reporters on Capitol Hill Thursday, Oct. 16, 2003 to discuss the United Nations-Iraq vote. (AP Photo/Terry Ashe) AP FILE Democratic presidential hopeful, and Senate Foreign Relations Committee Chairman Sen. Joseph Biden, D-Del., presides over a hearing of the committee on Capitol Hill in Washington, Thursday, Feb. 1, 2007 to discuss the remaining options in Iraq. (AP Photo/Dennis Cook) AP FILE Democratic presidential hopeful U.S. Sen. Joseph Biden D-Del., smiles during the Iowa Federation of Labor, AFL-CIO Presidential Forum Wednesday, Aug. 15, 2007, in Waterloo, Iowa. (AP Photo/M. Spencer Green) AP FILE January 31, 2007 - Files a statement of candidacy with the Federal Elections Commission to run for president. August 1, 2007 - His memoir, "Promises to Keep: On Life and Politics," is published. Sen. Joe Biden, D-Del., left, listens as Sen. Barack Obama, D-Ill., responds to a question during the first Democratic presidential primary debate of the 2008 election hosted by the South Carolina State University in Orangeburg, SC., Thursday, April 26, 2007. At right is Sen. Hillary Rodham Clinton, D-NY. (AP Photo/J. Scott Applewhite) AP FILE Sen. Joseph Biden, D-Del., speaks at a Caucus night rally in Des Moines, Iowa, Thursday, Jan. 3, 2008. Biden abandoned his bid for the Democratic presidential nomination Thursday after a poor showing in the state's caucuses. (AP Photo/Jeff Chiu) AP FILE In this Jan. 3, 2008, file photo, Democratic presidential hopeful, Sen. Joe Biden, D-Del., rests his head on the shoulder of his wife, Jill, as they stand in a hallway awaiting his introductions for a rally at the UAW Hall in Dubuque, Iowa on the day of the Iowa caucus in Dubuque, Iowa. (AP Photo/Mark Hirsch, File) AP FILE August 23, 2008 - Is named the vice-presidential running mate of Barack Obama. In this Aug. 23, 2008 file photo, Democratic presidential candidate Sen. Barack Obama D-Ill., and his vice presidential running mate Sen. Joe Biden, D-Del., appear together in Springfield, Ill. (AP Photo/M. Spencer Green, file) AP FILE In this Sept. 16, 2008 file photo, then Democratic vice presidential candidate Sen. Joe Biden, D-Del. arrives by Amtrak in Wilmington, Del., (AP Photo/Gerald Herbert, File) AP FILE In this Oct. 2,2008 file photo, Democratic vice presidential candidate Sen. Joe Biden, D-Del., left, and Republican vice presidential candidate Alaska Gov. Sarah Palin face off during the vice presidential debate at Washington University in St. Louis. (AP Photo/Tom Gannam, File) AP FILE November 4, 2008 - Is elected vice president of the United States. President-elect Barack Obama, left, and Vice President-elect Joe Biden wave to the crowd after Obama's acceptance speech at his election night party at Grant Park in Chicago before giving his acceptance speech Tuesday night, Nov. 4, 2008. (AP Photo/Morry Gash) AP FILE January 20, 2009 - Is sworn in as vice president of the United States. Vice President Joe Biden, left, with his wife Jill at his side, taking the oath of office from Justice John Paul Stevens at the U.S. Capitol in Washington, Tuesday, Jan. 20, 2009. (AP Photo/Elise Amendola) AP FILE February 7, 2009 - Delivers his first major speech as vice president at a security conference in Germany. US Vice President Joe Biden addresses the participants of the International Conference on Security Policy, Sicherheitskonferenz, at the hotel "Bayerischer Hof" in Munich, southern Germany, on Saturday, Feb. 7, 2009. AP FILE September 1, 2010 - Presides over a ceremony in Iraq to formally mark the end of the US combat mission in Iraq. US Vice President Joe Biden, left, US Secretary of Defense Robert Gates, center, and Chairman of the Joint Chiefs Admiral Mike Mullen, right, stand while the US National Anthem is played during the United States Forces-Iraq change of command ceremony in Baghdad on Wednesday Sept. 1, 2010, as a new US military mission in Iraq was launched ending seven years of combat. (AP Photo/Jim Watson Pool) AP FILE November 6, 2012 - Obama and Biden are reelected, defeating Mitt Romney and Paul Ryan. Vice President Joe Biden exits with his wife Jill Biden after voting at Alexis I. duPont High School, Tuesday, Nov. 6, 2012, in Greenville, Del. (AP Photo/Matt Rourke) AP FILE Vice President Joe Biden, with his wife Jill Biden, center, holding the Biden Family Bible, shakes hands with Supreme Court Justice Sonia Sotomayor after taking the oath of office during an official ceremony at the Naval Observatory, Sunday, Jan. 20, 2013, in Washington. (AP Photo/Carolyn Kaster) AP FILE October 2, 2014 - Speaking at the John F. Kennedy School of Government at Harvard University, Biden tells attendees that ISIS has been inadvertently strengthened by actions taken by Turkey, the UAE and other Middle Eastern allies to help opposition groups fighting against Syrian President Bashar al-Assad. In this Thursday, Oct. 2, 2014 file photo, Vice President Joe Biden speaks to students, faculty and staff at Harvard University in Cambridge, Mass. Biden is due to headline a Democratic campaign rally in Las Vegas, with a downtown appearance Monday, Oct. 6, 2014, to talk about raising the minimum wage. (AP Photo/Winslow Townson,File) AP FILE May 30, 2015 - Biden's eldest son, Beau Biden, passes away from brain cancer at age 46. In this June 6, 2015 file photo, Vice President Joe Biden, accompanied by his family, holds his hand over his heart as he watches an honor guard carry a casket containing the remains of his son, former Delaware Attorney General Beau Biden, into St. Anthony of Padua Roman Catholic Church in Wilmington, Del. for funeral services. Beau Biden died of brain cancer May 30 at age 46. (AP Photo/Patrick Semansky) AP FILE October 21, 2015 - Says he will not seek the presidency, announcing that the window for a successful campaign "has closed." December 6, 2016 - Doesn't rule out running for president in 2020, saying "I'm not committing not to run. I'm not committing to anything. I learned a long time ago fate has a strange way of intervening." President Barack Obama hugs Vice President Joe Biden as Biden waves at the end Biden's announcement in the Rose Garden of the White House in Washington, Wednesday, Oct. 21, 2015, that he will not run for the presidential nomination. Jill Biden is at right. (AP Photo/Jacquelyn Martin) AP FILE Vice President Joe Biden pauses between mock swearing in ceremonies in the Old Senate Chamber on Capitol Hill in Washington, Tuesday, Jan. 3, 2017, as the 115th Congress begins. (AP Photo/Alex Brandon) AP FILE January 12, 2017 - Obama surprises Biden by presenting him the Presidential Medal of Freedom, the nation's highest civilian honor, during a White House ceremony. President Barack Obama presents Vice President Joe Biden with the Presidential Medal of Freedom during a ceremony in the State Dining Room of the White House in Washington, Thursday, Jan. 12, 2017. (AP Photo/Susan Walsh) AP FILE February 1, 2017 - Biden and his wife, Jill Biden, launch the Biden Foundation, an organization that will work on seven issues: foreign policy; Biden's cancer initiative; community colleges and military families; protecting children; equality; ending violence against women; and strengthening the middle class. February 7, 2017 - Is named the Benjamin Franklin presidential practice professor at the University of Pennsylvania, where he will lead the Penn Biden Center for Diplomacy and Global Engagement. He will also serve as the founding chair of the University of Delaware's Biden Institute, the university announces. March 1, 2017 - Biden receives the Congressional Patriot Award from the Bipartisan Policy Center. He receives the honor in recognition of his work crafting bipartisan legislation with Republicans and Democrats. Former Vice President Joe Biden tucks notes into his jacket after speaking at an event to formally launch the Biden Institute, a research and policy center focused on domestic issues at the University of Delaware, in Newark, Del., Monday, March 13, 2017. (AP Photo/Patrick Semansky) AP FILE In this March 26, 2019, file photo, former Vice President Joe Biden speaks at the Biden Courage Awards in New York. (AP Photo/Frank Franklin II, File) AP FILE April 25, 2019 - Announces he is running for president in a campaign video posted to social media. Hours later, the Biden Foundation board chair, Ted Kaufman, announces the immediate suspension of all the organization's operations. Former Vice President and Democratic presidential candidate Joe Biden arrives at the Wilmington train station Thursday April 25, 2019 in Wilmington, Delaware. Biden announced his candidacy for president via video on Thursday morning. (AP Photo/Matt Slocum) AP FILE In this June 6, 2019, file photo, Democratic presidential candidate former Vice President Joe Biden speaks during the "I Will Vote" fundraising gala in Atlanta. Biden shifted to oppose longstanding restrictions on federal funding of abortion during his remarks. (AP Photo/John Bazemore, File) AP FILE Democratic presidential candidate, former Vice President Joe Biden signs a copy of his book "Promise Me, Dad" at a campaign rally at Modern Woodmen Park, Sunday, Jan. 5, 2020, in Davenport, Iowa. (AP Photo/Andrew Harnik) AP FILE Democratic presidential candidate former Vice President Joe Biden speaks at a primary night election rally in Columbia, S.C., Saturday, Feb. 29, 2020 after winning the South Carolina primary. (AP Photo/Gerald Herbert) AP FILE Democratic presidential candidate former Vice President Joe Biden speaks at a primary night election rally in Columbia, S.C., Saturday, Feb. 29, 2020, after winning the South Carolina primary. (AP Photo/Matt Rourke) AP FILE Democratic presidential candidate former Vice President Joe Biden speaks at a primary election night campaign rally Tuesday, March 3, 2020, in Los Angeles. (AP Photo/Chris Carlson) AP FILE August 20, 2020: Joe Biden accepts the Democratic nomination for president Democratic presidential candidate former Vice President Joe Biden speaks during the fourth day of the Democratic National Convention, Thursday, Aug. 20, 2020, at the Chase Center in Wilmington, Del. (AP Photo/Andrew Harnik) AP FILE Democratic presidential candidate former Vice President Joe Biden, with Democratic vice presidential candidate Sen. Kamala Harris, D-Calif., raise their arms up as fireworks go off in the background during the fourth day of the Democratic National Convention, Thursday, Aug. 20, 2020, at the Chase Center in Wilmington, Del. Looking on are Jill Biden, far left, and Harris' husband Doug Emhoff, far right. (AP Photo/Andrew Harnik) Andrew Harnik President Donald Trump, left, and Democratic presidential candidate former Vice President Joe Biden, right, with moderator Chris Wallace, center, of Fox News during the first presidential debate Tuesday, Sept. 29, 2020, at Case Western University and Cleveland Clinic, in Cleveland, Ohio. (AP Photo/Patrick Semansky) AP FILE Democratic presidential candidate former Vice President Joe Biden, right, and former President Barack Obama greet each other with an air elbow bump, at the conclusion of rally at Northwestern High School in Flint, Mich., Saturday, Oct. 31, 2020. (AP Photo/Andrew Harnik) AP FILE Democratic presidential candidate former Vice President Joe Biden arrives to speak at a rally at Belle Isle Casino in Detroit, Mich., Saturday, Oct. 31, 2020, which former President Barack Obama also attended. (AP Photo/Andrew Harnik) AP FILE President-elect Joe Biden gestures on stage after speaking, Saturday, Nov. 7, 2020, in Wilmington, Del. (AP Photo/Andrew Harnik, Pool) Andrew Harnik FILE - In this Saturday, Nov. 7, 2020, file photo, from left, Doug Emhoff, husband of Vice President-elect Kamala Harris, Harris, President-elect Joe Biden and his wife, Jill Biden, stand on stage together, in Wilmington, Del. The theme for Biden’s inauguration will be “America United." Unity is an issue that’s long been a central focus for Biden but one that’s taken on added weight in the wake of the violence at the U.S. Capitol. (AP Photo/Andrew Harnik, Pool, File) Andrew Harnik President-elect Joe Biden announces his climate and energy team nominees and appointees at The Queen Theater in Wilmington Del., Saturday, Dec. 19, 2020. (AP Photo/Carolyn Kaster) AP FILE President Joe Biden speaks about his domestic agenda from the East Room of the White House in Washington on Oct. 28, 2021. (AP Photo/Susan Walsh) AP FILE U.S. President Joe Biden, left, shakes hands with Pope Francis as they meet at the Vatican on Oct. 29, 2021. (Vatican Media via AP) AP FILE President Joe Biden removes his face mask as he arrives in the East Room of the White House to speak about the evacuation of American citizens, their families, special immigrant visa applicants and vulnerable Afghans on Aug. 20, 2021, in Washington. (AP Photo/Manuel Balce Ceneta) AP FILE Cherelle Griner, wife of WNBA star Brittney Griner, speaks after President Joe Biden announced Brittney Griner's release in a prisoner swap with Russia on Dec. 8, 2022, in the Roosevelt Room of the White House in Washington. Also attending are Secretary of State Antony Blinken, left, and Vice President Kamala Harris. Patrick Semansky, Associated Press President Joe Biden holds the microphone to Chocolate, the national Thanksgiving turkey, during a pardoning ceremony Nov. 21, 2022, at the White House in Washington. Andrew Harnik President Joe Biden holds an Atlanta Braves jersey during an event celebrating the Major League Baseball 2021 World Series champion Atlanta Braves in the East Room of the White House on Sept. 26, 2022, in Washington. Evan Vucci, Associated Press President Joe Biden receives his COVID-19 booster from a member of the White House medical unit during an event in the South Court Auditorium on the White House campus on Oct. 25, 2022, in Washington. Evan Vucci, Associated Press President Joe Biden and first lady Jill Biden arrive to give treats to trick-or-treaters on the South Lawn of the White House, on Halloween on Oct. 31, 2022, in Washington. Alex Brandon, Associated Press U.S. President Joe Biden, left, talks with Indonesian President Joko Widodo during their bilateral meeting ahead of the G20 Summit in Nusa Dua, Bali, Indonesia, on Nov. 14, 2022. Achmad Ibrahim, Associated Press U.S. President Joe Biden, right, and Chinese President Xi Jinping shake hands before a meeting on the sidelines of the G20 summit meeting Nov. 14, 2022, in Bali, Indonesia. Alex Brandon President Joe Biden is greeted by Israeli Prime Minister Benjamin Netanyahu after arriving at Ben Gurion International Airport on Oct. 18, 2023, in Tel Aviv. Evan Vucci, Associated Press President Joe Biden speaks from the Oval Office of the White House on Oct. 19, 2023, in Washington, about the war in Israel and Ukraine. Jonathan Ernst, Associated Press President Joe Biden arrives to speak at the Amtrak Bear Maintenance Facility on Nov. 6, 2023, in Bear, Del. Andrew Harnik President Joe Biden, accompanied by Office of Management and Budget director Shalanda Young, left, and Women's Alzheimer's Movement founder Maria Shriver, right, gives first lady Jill Biden a kiss after giving her the pen he used to sign a presidential memorandum that will establish the first-ever White House Initiative on Women's Health Research in the Oval Office of the White House on Nov. 13, 2023, in Washington. Andrew Harnik, Associated Press President Joe Biden pauses as he speaks to reporters in Nantucket, Mass. on Nov. 26, 2023, about hostages freed by Hamas in a third set of releases under a four-day cease-fire deal between Israel and Hamas. Stephanie Scarbrough, Associated Press President Joe Biden shakes hands with Ukrainian President Volodymyr Zelenskyy as they meet in the Oval Office of the White House on Dec. 12, 2023, in Washington. Evan Vucci President Joe Biden and Ukrainian President Volodymyr Zelenskyy depart a news conference in the Indian Treaty Room in the Eisenhower Executive Office Building on the White House Campus on Dec. 12, 2023, in Washington. Andrew Harnik President Joe Biden speaks during a funeral service for retired Supreme Court Justice Sandra Day O'Connor at the Washington National Cathedral on Dec. 19, 2023, in Washington. O'Connor, an Arizona native and the first woman to serve on the nation's highest court, died Dec. 1, 2023, at age 93. Jacquelyn Martin President Joe Biden arrives to deliver remarks on the economy on June 28, 2023, at the Old Post Office in Chicago. Evan Vucci, Associated Press President Joe Biden, right, stands as an Army carry team moves the transfer case containing the remains of U.S. Army Sgt. Kennedy Ladon Sanders, 24, of Waycross, Ga., at Dover Air Force Base, Del., on Feb. 2, 2024. Sanders was killed in a drone attack in Jordan on Jan. 28, 2024. Matt Rourke, Associated Press President Joe Biden speaks during the State of the Union address on Capitol Hill on March 7, 2024, in Washington, as Vice President Kamala Harris and House Speaker Mike Johnson listen. Mark Schiefelbein, Associated Press Vice President Kamala Harris embraces President Joe Biden after a speech on health care in Raleigh, N.C., on March. 26, 2024. Matt Kelley, Associated Press President Joe Biden greets Zion Schrode, 8 months, of Marin County, Calif., as he is held by his mother Erin Schrode during a Jewish American Heritage Month event, on May 20, 2024, in the Rose Garden of the White House in Washington. Jacquelyn Martin, Associated Press Kansas City Chiefs coach Andy Reid, left, and CEO Clark Hunt, right, watch as President Joe Biden, center, puts on a Chiefs helmet during an event with the Super Bowl-champion Kansas City Chiefs on the South Lawn of the White House, on May 31, 2024, to celebrate their championship season and victory in Super Bowl LVIII. Evan Vucci, Associated Press President Joe Biden and first lady Jill Biden walk in the Normandy American Cemetery following a ceremony to mark the 80th anniversary of D-Day, on June 6, 2024, in Normandy. Evan Vucci U.S. President Joe Biden, right, greets Pope Francis ahead of a working session on Artificial Intelligence (AI), Energy, Africa-Mediterranean, on day two of the 50th G7 summit at Borgo Egnazia, southern Italy, on June 14, 2024. Christopher Furlong, Associated Press President Joe Biden speaks during a campaign event with former President Barack Obama moderated by Jimmy Kimmel at the Peacock Theater on June 15, 2024, in Los Angeles. Alex Brandon, Associated Press President Joe Biden, right, and Republican presidential candidate former President Donald Trump, left, participate in a presidential debate hosted by CNN on June 27, 2024, in Atlanta. Gerald Herbert, Associated Press First lady Jill Biden, President Joe Biden, Vice President Kamala Harris, and second gentleman Douglas Emhoff view the Independence Day firework display over the National Mall from the balcony of the White House, on July 4, 2024, in Washington. Evan Vucci, Associated Press President Joe Biden, right, and the Rev. Dr. J. Louis Felton pray at a church service at Mt. Airy Church of God in Christ on July 7, 2024, in Philadelphia. Manuel Balce Ceneta, Associated Press President Joe Biden addresses the nation from the Oval Office of the White House in Washington on July 14, 2024, about the assassination attempt of Republican presidential candidate former President Donald Trump at a campaign rally in Pennsylvania. Erin Schaff, Associated Press President Joe Biden pauses as he speaks at the Biden campaign headquarters in Wilmington, Del., on Feb. 3, 2024. Alex Brandon, Associated Press President Joe Biden walks on stage to speak during the NAACP national convention July 16, 2024, in Las Vegas. David Becker, Associated Press President Joe Biden walks between tombstones as he arrives to attend a mass at St. Joseph on the Brandywine Catholic Church in Wilmington, Del., on July 6, 2024. Manuel Balce Ceneta, Associated Press
AGNC INVT 1000 DR REP 1 SRS F PRF declares $0.3828 dividendUS auto giant General Motors announced Tuesday it will abandon its robotaxi development efforts after a highly publicized incident last year stymied its progress in the autonomous vehicle field. The Detroit-based manufacturer plans to merge the Cruise robotaxi vehicle unit with GM's technical teams to concentrate on developing advanced driver assistance systems for personal vehicles, a statement said. The company said it abandoned the Cruise project "given the considerable time and resources that would be needed to scale the business, along with an increasingly competitive robotaxi market." It marks a major turnaround for GM, which bought the Cruise startup in 2016 and has since spent billions of dollars to make the operation viable. "A robotaxi business is not General Motors’ core business," said GM CEO Mary Barra in a call with analysts. But Barra said GM's commitment to autonomous technology "is unwavering." The halt of operations comes a year after Cruise was forced to suspend all operations in San Francisco after one of its self-driving cars dragged a woman who had first been hit by a hit-and-run driver in the city. Cruise lost its operating permits from regulators, paused expansions into other states and laid off 900 employees -- a quarter of its workforce. Shortly before the incident, California authorities had allowed for expanded driverless taxi services in San Francisco, giving the go-ahead for Alphabet-owned Waymo and Cruise. Cruise's exit confirms Waymo as the dominant player in the business, which was valued at $45 billion after a fundraising round in October, according to Bloomberg. The company has been expanding its reach and currently runs robotaxi fleets in San Francisco, Phoenix and Los Angeles. And in a team-up with Uber, the company is planning to offer Waymo robotaxi rides in Atlanta and Austin. Amazon's Zoox meanwhile is conducting robotaxi testing in California and Las Vegas, while Elon Musk recently unveiled what he said was a robotaxi capable of self-driving, predicting it would be available by 2027. GM's strategic pivot comes as embattled automakers worldwide face mounting pressure to balance investments in emerging technologies with near-term profitability. The auto giant said that the restructuring is expected to generate annual savings exceeding $1 billion once completed in the first half of 2025. GM's share price was up by more than three percent in after hours trading on Wall Street. arp/dw
Shiffrin crashes out of Killington giant slalom won by Hector